EU-IN_VITRO_MEDICAL_DEVICE_REG-ART_5_2_ANX_1

In Vitro Diagnostic Medical Devices Regulation - Hazardous Substances

EU. Hazardous Substances for Purposes of Art. 5(2) and Annex I of Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices, 5 May 2017, as corrected 27 December 2019

This list contains a non-exhaustive inventory of hazardous substances for purposes of Regulation (EU) 2017/746, including Chap. 2 (Placing on the market and putting into service) and Annex I (General Safety and Performance Requirements). It is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list).

Last updated 26 apríla 2024. Database contains 4917 unique substances/entries.

Filter the list

Ukazujem 3 801 - 3 850 z 4 917 výsledkov.

Substance Name	EC No.	CAS No.	EU CLP (1272/2008)	EU_BA Directive 2000/54/EC	EU REACH: List of SVHC
Pitch, coal tar, low-temp; Pitch Residue [A complex black solid or semi-solid obtained from the distillation of a low temperature coal tar. It has a softening point within the approximate range of 40 °C to 180 °C (104°F to 356 °F). Composed primarily of a complex mixture of hydrocarbons.] A complex black solid or semi-solid obtained from the distillation of a low temperature coal tar. It has a softening point within the approximate range of 40°C to 180°C (104°F to 356°F). Composed primarily of a complex mixture of hydrocarbons.	292-651-4	90669-57-1	Carc. 1B			Details
Pitch, coal tar-petroleum; Pitch Residues [The residue from the distillation of a mixture of coal tar and aromatic petroleum streams. A solid with a softening point from 40°C to 180°C (140°F to 356°F). Composed; primarily of a complex combination of three or more membered condensed ring aromatic hydrocarbons.] The residue from the distillation of a mixture of coal tar and aromatic petroleum streams. A solid with a softening point from 40°C to 180°C (104°F to 356°F). Composed primarily of a complex combination of three or more membered condensed ring aromatic hydrocarbons.	269-109-0	68187-57-5	Carc. 1B			Details
Pitch; Pitch	263-072-4	61789-60-4	Carc. 1B			Details
Plasmodium falciparum	-	-		P Parasites		Details
Plasmodium spp. (human and simian)	-	-		P Parasites		Details
platinum(IV) nitrate/nitric acid solution	432-400-1	10102-09-7	Skin Corr. 1A			Details
Plesiomonas shigelloides	-	-		B Bacteria and similar species		Details
Polioviruses	-	-		V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans.		Details
poly(oxo(2-butoxyethyl-3-oxobutanoato-O'1,O'3)aluminium) AOC 2050X	403-430-0	138360-92-6	Eye Dam. 1			Details
poly(oxypropylenecarbonyl-co-oxy(ethylethylene)carbonyl), containing 27 % hydroxyvalerate BIOPOL HX	403-300-3	127536-43-0	Skin Sens. 1			Details
poly-(methyl methacrylate)-co-(butylmethacrylate)-co-(4-acryloxybutyl-isopropenyl-α, α-dimethylbenzyl carbamate)-co-(maleicanhydride) RX-33	419-590-1	-	Flam. Sol. 1; Skin Sens. 1			Details
poly-[((4-((4-(ethyl-ethylene)amino)phenyl)-(4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)-3-methylcyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate]	427-480-8	176429-22-4	STOT SE 3; Skin Irrit. 2; Eye Dam. 1			Details
poly-[((4-((4-ethyl-ethylene)amino)phenyl)-((4-(ethyl-(2-oxyethylene)amino)phenyl)methinyl)cyclohexa-2,5-dienylidene)-N-ethyl-N-(2-hydroxyethyl)ammonium acetate]	427-280-0	176429-27-9	STOT SE 3; Skin Irrit. 2; Eye Dam. 1			Details
polychlorobiphenyls; PCB	215-648-1	1336-36-3	STOT RE 2			Details
Polyethylene glycol mono(tert-octylph-enyl) ether9036-19-5	618-541-1	9036-19-5			ENDE Endocrine disrupting properties (Article 57(f) - environment)	Details
polyhexamethylene biguanide hydrochloride; PHMB	608-723-9	32289-58-0	Carc. 2; Acute Tox. 2; Acute Tox. 4; STOT RE 1; Eye Dam. 1; Skin Sens. 1B			Details
polyhexamethylene biguanide hydrochloride; PHMB	608-042-7	27083-27-8	Carc. 2; Acute Tox. 2; Acute Tox. 4; STOT RE 1; Eye Dam. 1; Skin Sens. 1B			Details
polymer of allylamine hydrochloride PAA HCL; PAA HCL 10L; PAA HCL 10S; PAA HCL 3L; PAA HCL 3S; PAA HCL H; PAA HCL L	415-050-2	71550-12-4	Acute Tox. 4; Skin Sens. 1			Details
polymeric reaction product of bicyclo[2.2.1]hepta-2,5-diene, ethene, 1,4-hexadiene, 1-propene with N, N-di-2-propenylformamide X4060	404-035-6	1379801-27-0	Skin Sens. 1			Details
Porphyromonas spp.	-	-		B Bacteria and similar species		Details
potasan; O, O-diethyl O-(4-methylcoumarin-7-yl) phosphorothioate	-	299-45-6	Acute Tox. 2; Acute Tox. 1			Details
potassium	231-119-8	7440-09-7	Water-react. 1; Skin Corr. 1B			Details
potassium (E,E)-hexa-2,4- dienoate	246-376-1	24634-61-5	Eye Irrit. 2			Details
potassium (oxido-NNO-azoxy)cyclohexane; cyclohexylhydroxydiazene 1-oxide, potassium salt; [K-HDO]	613-953-8	66603-10-9	Flam. Sol. 1; Acute Tox. 3; STOT RE 2; Skin Irrit. 2; Eye Dam. 1			Details
potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate [containing < 0,5 % N, N-dimethylformamide (EC no; 200-679-5)];potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate [containing ≥ 0,5 % N, N-dimethylformamide (EC No 200-679-5)]	418-260-2	183196-57-8	Repr. 1B; Skin Sens. 1			Details
potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate [containing < 0,5 % N, N-dimethylformamide (EC no; 200-679-5)];potassium 1-methyl-3-morpholinocarbonyl-4-[3-(1-methyl-3-morpholinocarbonyl-5-oxo-2-pyrazolin-4-ylidene)-1-propenyl]pyrazole-5-olate [containing ≥ 0,5 % N, N-dimethylformamide (EC No 200-679-5)]	418-260-2	183196-57-8	Skin Sens. 1			Details
Potassium 2,3,3,3-tetrafluoro-2-(heptafluoropropoxy)propionate	266-578-3	67118-55-2			E Equivalent level of concern having probable serious effects to the environment (Article 57(f) - environment) HH Equivalent level of concern having probable serious effects to human health (Article 57(f) - human health)	Details
potassium 2,5-dichlorobenzoate POTASSIUM 2,5-DICHLOROBENZOATE	415-700-5	184637-62-5	Acute Tox. 4; Eye Dam. 1			Details
potassium 2-(2,4-dichlorophenoxy)-(R)-propionate DUPLOSAN-DP-KALIUM	413-580-9	113963-87-4	Acute Tox. 4; Skin Irrit. 2; Eye Dam. 1; Skin Sens. 1			Details
potassium 2-amino-2-methylpropionate octahydrate FLEXSORB HP SOLID; MALINE K	405-560-3	120447-91-8	Acute Tox. 4; Skin Corr. 1A			Details
potassium 2-chloro-3-(benzyloxy)propionate KLOBENPROP	426-350-8	138666-92-9	Acute Tox. 4; STOT RE 2; Eye Dam. 1; Skin Sens. 1			Details
potassium 2-hydroxycarbazole-1-carboxylate AZYLACID-POTASSIUMSALT	401-630-2	96566-70-0	Acute Tox. 4; Eye Irrit. 2; STOT SE 3			Details
potassium 3,6-dichloro-o-anisate	233-002-7	10007-85-9	Eye Irrit. 2			Details
potassium 3-iodo-6-methylbenzenesulfonate	426-300-5	-	Eye Dam. 1			Details
potassium 4-(11-methacrylamidoundecanamido)benzenesulfonate V67282	406-500-9	174393-75-0	Skin Sens. 1			Details
potassium 4-iodo-2-sulfonato-benzoic acid	426-620-5	619297-89-1	Eye Dam. 1			Details
potassium bifluoride; potassium hydrogen difluoride	232-156-2	7789-29-9	Acute Tox. 3; Skin Corr. 1B			Details
potassium bis(N-carboxymethyl)-N-methyl-glycinato-(2-)N, O,O, N)-ferrate-(1-)monohydrate CHEMICAL CHELATING AGENT #2	411-640-9	153352-59-1	Acute Tox. 4			Details
potassium bromate	231-829-8	7758-01-2	Ox. Sol. 1; Carc. 1B; Acute Tox. 3			Details
potassium chlorate	223-289-7	3811-04-9	Ox. Sol. 1; Acute Tox. 3			Details
potassium chromate	232-140-5	7789-00-6	Carc. 1B; Muta. 1B; Eye Irrit. 2; STOT SE 3; Skin Irrit. 2; Skin Sens. 1		C Carcinogenic (article 57a) M Mutagen (article 57b)	Details
potassium cyanate	209-676-3	590-28-3	Acute Tox. 4			Details
potassium dichromate	231-906-6	7778-50-9	Ox. Sol. 2; Carc. 1B; Muta. 1B; Repr. 1B; Acute Tox. 2; Acute Tox. 3; STOT RE 1; Acute Tox. 4; Skin Corr. 1B; Resp. Sens. 1; Skin Sens. 1		C Carcinogenic (article 57a) M Mutagen (article 57b) R Toxic for reproduction (article 57c)	Details
potassium ethanolate; potassium ethoxide	213-029-0	917-58-8	Self-heat. 1; Skin Corr. 1B			Details
potassium ferrite	430-010-4	12160-44-0	Skin Corr. 1B; Skin Sens. 1			Details
potassium fluoride	232-151-5	7789-23-3	Acute Tox. 3			Details
potassium hydrogensulphate	231-594-1	7646-93-7	Skin Corr. 1B; STOT SE 3			Details
potassium hydroxide; caustic potash	215-181-3	1310-58-3	Acute Tox. 4; Skin Corr. 1A			Details
Potassium hydroxyoctaoxodizincatedichromate	-	-			C Carcinogenic (article 57a)	Details
potassium iron(III) 1,3-propanediamine-N, N,N',N'-tetraacetate hemihydrate FEKPDTA; KFEPDTA	405-680-6	148434-01-9	Self-heat. 2			Details

Ukazujem 3 801 - 3 850 z 4 917 výsledkov.

Export search results to:

EU-IN_VITRO_MEDICAL_DEVICE_REG-ART_5_2_ANX_1

EU-IN_VITRO_MEDICAL_DEVICE_REG-ART_5_2_ANX_1

In Vitro Diagnostic Medical Devices Regulation - Hazardous Substances

EU. Hazardous Substances for Purposes of Art. 5(2) and Annex I of Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices, 5 May 2017, as corrected 27 December 2019

RELEVANT LEGISLATION

Contact EUCLEF Helpdesk

Last updated 26 apríla 2024. Database contains 4917 unique substances/entries.

Footer Nav Items